Aggregated from the cited literature below. We summarize sources — we don't author claims.
Lixisenatide (a GLP-1 receptor agonist) is discussed as a short-acting GLP-1RA option used once daily for type 2 diabetes. Research summarized in the provided sources also describes effects shared across GLP-1 receptor agonists, including augmentation of glucose-dependent insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction of calorie intake/body weight. Separate studies specifically evaluated lixisenatide in cardiovascular outcomes in type 2 diabetes with recent acute coronary syndrome and in a phase 2 trial in early Parkinson’s disease.
Mechanism (as reported)
Mechanistic summaries in the provided sources describe GLP-1 receptor agonists (including short-acting agents such as lixisenatide) as increasing hyperglycemia-induced insulin secretion, suppressing glucagon secretion (at hyper- or euglycemia), and slowing gastric emptying; additional described class effects include reduction of calorie intake and body weight. Short-acting GLP-1RAs (including lixisenatide) are described as primarily lowering postprandial blood glucose through inhibition of gastric emptying.
Key findings (each cites a source)
A state-of-the-art review described GLP-1 receptor agonists as being used for type 2 diabetes with regimens that include once-daily dosing with lixisenatide (contrasted with twice-daily exenatide and once-weekly GLP-1RAs). [PMID 33068776]
The provided sources described shared GLP-1 receptor agonist class mechanisms as including augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying, and reduction in calorie intake/body weight. [PMID 33068776]
A review of individualized treatment described GLP-1 biology and reported that short-acting GLP-1 receptor agonists (including lixisenatide) primarily lower postprandial blood glucose through inhibition of gastric emptying. [PMID 22945360]
A phase 2, double-blind, randomized, placebo-controlled trial (LIXIPARK) reported that lixisenatide led to less progression of motor disability than placebo at 12 months in participants with early Parkinson’s disease, using the MDS-UPDRS part III as the primary end point; the same report noted gastrointestinal side effects (nausea and vomiting) and that longer/larger trials are needed. [PMID 38598572]
A randomized trial in type 2 diabetes with recent acute coronary syndrome (ELIXA) reported that adding lixisenatide to usual care showed noninferiority to placebo for a composite cardiovascular end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) but did not show superiority; it also reported no significant between-group differences in hospitalization for heart failure or death and no higher rates of several serious adverse outcomes compared with placebo. [PMID 26630143]
An obesity review stated that GLP-1 agonists (class) have been shown to be effective in promoting weight loss and summarized effects including improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic and renal protection outcomes based on studies it reviewed. [PMID 37445623]
A breastfeeding-focused source stated there is no information available on clinical use of lixisenatide during breastfeeding and suggested that because lixisenatide is a large peptide molecule, the amount in milk is likely to be very low and absorption is unlikely; it advised caution until more data are available, especially with newborns or preterm infants. [PMID 30000034]
Independent test grades
No independent third-party test data is available for Lixisenatide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (10)
Consolidated from PubMed — each links to the original record.
Lixisenatide (Adlyxin, Lyxumia, ZP10A peptide) is classified under glp-1 & incretin agonists, which has been withdrawn from approved use. Research goals associated with it include metabolic & weight.
Is Lixisenatide FDA-approved?
Lixisenatide has been withdrawn from approved use.
What does the research on Lixisenatide say?
peptideone aggregates 10 references from PubMed for Lixisenatide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.